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Presentation of the study 
  
The research work performed during my PhD investigates the relationship between the evolutionary 
conserved xenobiotic sensor Aryl Hydrocarbon Receptor (AHR) and the pathway of Interleukin-6 
(IL6), a cytokine frequently involved in inflammation. The physiologic expression of both AHR 
and IL6 is tightly regulated by different mechanisms and dysregulations in the control of their 
activity have been associated with several adverse outcomes, such as cancer. Here, we analysed 
their mutual regulation in two different experimental models. The first is a human epithelial breast 
cell model with an IL6-driven acute inflammation induction. The results on cellular lines have been 
obtained at the University of Bologna and are described in this thesis as “project 1”. The second one 
is a mice model, triple-knockout for the AHR target genes Cyp1a1/1a2/1b1 (CYP1-KO). The 
experiments on mice have been conducted at the Karolinska Institutet during my experience abroad 
and are named in this manuscript as “project 2”. Starting from current data demonstrating that AHR 
mediates the induction of IL6, the aim of this study was:  
- to evaluate if, in a human epithelial breast cell model, inflammation driven by IL6 could, in 
turn, regulate the expression of AHR thus creating an interplay between AHR and IL6, and 
to evaluate thus whether AHR could assume a role in sustaining inflammation; 
- to investigate whether the CYP1-KO mouse model, which is characterized by a potentiated 
activation of AHR, presented an induced expression of Il6 or other inflammation-related 
features, or adverse effects in pathways in which AHR exerts physiological functions. 
Our results indicate that: i) IL6 administration stimulates STAT3 and AHR expression through the 
activation of pSTAT3; ii) The induction of endogenous IL6 is regulated by IL6 administration and 
by AHR activation; iii) IL6 affects cell cycle progression and migration activity; iv) AHR/CYP1 
disrupted signaling does not interfere with Il6 expression, but affects Pparγ and Ahr transcription 
and mammary gland tissue morphology. These results demonstrate that, in the human epithelial 
breast cell line MCF10A, AHR could assume an active role in the complex puzzle of early steps of 
inflammation. In the CYP1-KO we did not identify an altered expression of Il6 indicating that an 
altered CYP1/AHR signaling does not interfere with IL6-related pathway. However, in contrast, we 
could observe an altered expression of Pparγ, an important marker in adipogenesis.  
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 List of abbreviations:  
 
 
AHR  Aryl Hydrocarbon Receptor 
 
IL6  Interleukin-6  
 
STAT3 Signal Transducer and Activator of Transcription 3 
 
pSTAT3 Phospho- Signal Transducer and Activator of Transcription 3 
 
CPT   Cryptotanshinone 
 
FICZ  6-formylindolo[3,2-b]carbazole 
 
TCDD  2,3,7,8-Tetrachlorodibenzo-p-dioxin 
 
TNBC  Triple Negative Breast Cancer 
 
TEBs  Terminal End Buds 
 
PPARγ Peroxisome Proliferator-Activated Receptor Gamma 
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1. INTRODUCTION 
 
Everyday most animals, including humans, are exposed to a myriad of chemicals through the food 
chain, air and water. Some of these molecules carry relevant information about the animal’s 
environment, such as the presence of food or predators, whereas others are dangerous and toxic and 
therefore must be avoided or eliminated. Several mechanisms have been developed throughout 
evolution to recognize a wide range of chemical structures and to initiate appropriate/opportune 
responses. Large families of olfactory/chemosensory receptors can detect volatile and soluble 
chemicals in the environment (Mombaerts, 1999) and stimulate numerous neural pathways. In 
addition to this system, inducible enzymes and transporters have developed to mediate the 
biotransformation and elimination of the environmental toxic compounds (Brattsten, 1979; Nebert 
& Gonzalez, 1987). The enzymatic components of this system include the cytochrome P450 
superfamily, and the sensory components involve receptors that regulate the expression of the 
biotransformation and transporter genes, in response to environmental chemicals. These receptors 
include the aryl hydrocarbon receptor (AHR), a member of the basic-helix-loop-helix (bHLH)–Per-
ARNT-Sim (PAS) gene superfamily.  
 
1.1 BHLH-PAS PROTEINS 
 
Basic HLH (helix–loop–helix)–PER–ARNT–SIM (bHLH–PAS) proteins are a family of 
heterodimeric transcription factors found throughout all three kingdoms of life that sense and 
respond to environmental pollutants or to physiological signals through their two PAS domains and 
are involved in dimerization, DNA binding and signal transduction. Dimers are formed between a 
class I factor, that can be tissue restricted or activated in response to a stimulus, and a more 
ubiquitous or unregulated class II factor (figure 1).  
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Figure 1. Roles and structures of class I and class II bHLH–PAS family members (Bersten, Sullivan, Peet, & Whitelaw, 
2013) 
 
These proteins have a broad range of roles in physiological processes related to homeostasis and to 
the stress response (Furness, Lees, & Whitelaw, 2007; McIntosh, Hogenesch, & Bradfield, 2010; 
Michaud et al., 2001; Ramamoorthi et al., 2011). An example of class I and class II interaction is 
the circadian locomotor output cycles kaput (CLOCK) and NPAS2 circadian rhythm factors, which 
dimerize with the protein brain muscle BMAL. This leads to the expression of genes encoding 
period (PER) and cryptochrome (CRY) proteins that subsequently translocate into the nucleus 
where they repress the transcriptional activity of BMAL and CLOCK proteins (McIntosh et al., 
2010), activating thus transcriptional and translational feedback loops that comprise the core 
circadian clock machinery that control diurnal oscillation of physiological functions. The cycle 
takes approximately 24 hours to complete, thus describing the circa (near) diem (day) rhythm.  
Another example of bHLH-PAS interaction is the dimerization between class I aryl hydrocarbon 
receptor (AHR) and class II AHR nuclear translocator (ARNT) proteins that induce transcription of 
genes for a range of biological outputs, such as detoxification, cellular homeostasis and immune 
responses.   
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1.2 ARYL HYDROCARBON RECEPTOR 
 
1.2.1 Background 
Research in AHR began more than 50 years ago, after the earliest studies describing the induction 
of enzymes by foreign chemicals (Conney, Gillette, Inscoe, Trams, & Posner, 1959; Conney, 
Miller, & Miller, 1956, 1957) and the identification of the cytochrome P450 (Omura & Sato, 1962). 
The first evidentiary findings of AHR occurred in 1974 and 1976, when Poland and Nebert 
identified a cytoplasmatic factor that bound TCDD with high affinity, and called it aryl hydrocarbon 
receptor (A. Poland, Glover, & Kende, 1976; A. P. Poland, Glover, Robinson, & Nebert, 1974). 
Subsequently, in 1992 Ema and colleagues were able to clone the mouse Ahr gene (Ema et al., 
1992) and in 1995 Fernandez-Salguero and coworkers (Fernandez-Salguero et al., 1995) created the 
first Ahr(-/-) knockout mouse line, a model that would become a valuable system with which to 
study the AHR-CYP1 pathway. A timeline of the AHR-signaling story is shown in table 1.  
 
Table 1. Timeline of AHR history (Nebert, 2017) 
 
Year Discovery 
 
1956 “Benzpyrene hydroxylase” activity induced by PAHs in rat liver 
1962 Benzpyrene hydroxylase activity induced throughout rat GI tract by oral benzpyrene 
1968 “AHH activity” assay designed; AHH induction by PAHs in fetal hamster cell cultures 
1969 Diﬀerences in AHH inducibility by PAHs between inbred strains of mice 
1970 PAH-induced AHH activity represents a cytochrome P450 (P1-450) 
1972 PAH-induced AHH activity in B6 × D2 crosses exhibits predominantly Mendelian inheritance 
1972 In utero AHH induction in fetuses by treatment of mother with PAHs 
1973-1989 Importance of AHR-mediated CYP1 shown for cancer, mutagenesis, toxicity, and teratogenesis 
1974 Evidence of AHR, based on dose-response curve: AHH induction as a function of TCDD concentration in B6 vs D2 
inbred mouse strains 
1976 Radiolabeled TCDD binding assay detects cytosolic AHR 
1979 Development of benzo[a]pyrene-resistant clones in Hepa-1 cells: c1 & c37, c2, and c4 
1980 AHR-mediated CYP1A1-induced sister-chromatid-exchange detected in GD7.5 embryo 
1981, 1989 AHR-mediated P1-450 induction proposed to be involved in inﬂammatory process 
1982 Intranuclear appearance of radiolabeled TCDD (AHR) asspcoated with P1-450 induction 
1988, 1998 AHR-mediated CYP1A1 induction demonstrated in GD0.5 one-cell zygote 
1991 Mouse Arnt gene cloned (human ARNT gene shortly thereafter) 
1991 The term “bHLH/PAS” was ﬁrst coined 
1992 Mouse Ahr gene cloned (human AHR gene shortly thereafter) 
1995 Creation of ﬁrst of several Ahr(−/−) knockout mouse lines 
1996 Standardized gene nomenclature for CYP genes in all species becomes well established 
2005 AHR-CYP1 axis demonstrated in cultured ES cells 
2008, 2013 Underscoring the importance of AHR-CYP1 axis in LM second-messenger pathways involving innumerable critical life 
events — in virtually every organ, tissue and cell-type 
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1.2.2 AHR structure  
The human AHR gene consists of 11 exons encoded on chromosome 7 (Ema et al., 1994), the 
protein is composed of 848 amino acids and has a molecular mass of 96 kDa, while the murine 
ortholog consists of 11 exons encoded on chromosome 12 (Schmidt, Carver, & Bradfield, 1993). 
The protein has 805 amino acids and a molecular mass of 90 kDa (figure 2). 
 
 
Figure 2. Mouse and human AHR (I. A. Murray, Patterson, & Perdew, 2014) 
 
1.2.3 AHR ligands 
The AHR is activated and/or bound by various classes of both endogenous and exogenous 
compounds. Among the endogenous are tryptophan derivatives, including FICZ (A. Rannug et al., 
1987; U. Rannug et al., 1995; Y. D. Wei, Helleberg, Rannug, & Rannug, 1998), kynurenine (Heath-
Pagliuso et al., 1998), fatty acid metabolites such as lipoxin A4 (Schaldach, Riby, & Bjeldanes, 
1999) and tertapyrroles as bilirubin (Adachi et al., 2001), which have been isolated as natural 
ligands of AHR. Exogenous ligands are represented by xenobiotic compounds that can be either 
natural, such as the combustion-derived polycyclic aromatic hydrocarbon benzo[a]pyrene (B[a]P), 
or synthetic such as polychlorinated biphenyls (PCBs) and halogenated aromatic hydrocarbons 
1. Introduction 
 
 
 
  8 
 
including 2,3,7,8-tetrachlorodibenzodioxin (TCDD) (Denison & Nagy, 2003; Denison, Soshilov, 
He, DeGroot, & Zhao, 2011). 
 
1.2.4 AHR mechanism  
The molecular pathway leading to AHR activation by xenobiotics has been extensively studied 
(figure 3). In the absence of a ligand, the AHR resides in the cellular cytoplasm, bound to a 
molecular chaperone complex formed by two HSP90 molecules (Denis, Cuthill, Wikstrom, 
Poellinger, & Gustafsson, 1988), the 23-kDa co-chaperone p23 (Kazlauskas, Poellinger, & 
Pongratz, 1999), and the immunophilin-like AHR interacting protein AIP (also known as XAP2 or 
ARA9)(Ma & Whitlock, 1997). Upon ligand binding, the AHR protein undergoes conformational 
changes, the cofactors dissociate and the receptor translocates to the cellular nucleus where 
heterodimerizes with the class II bHLH protein ARNT (Probst, Reisz-Porszasz, Agbunag, Ong, & 
Hankinson, 1993). This heterodimer binds to a set of co-activators and/or corepressors and the 
resulting complex, being transcriptionally active, binds to XRE motifs containing the core bases 5’-
GCGTG-3’ located in the upstream regulatory region of target genes (Mimura, Ema, Sogawa, & 
Fujii-Kuriyama, 1999). DNA binding of the AHR/ARNT dimer leads to the recruitment of different 
histone acetyltransferases or histone modifiers that relax the local chromatin structure, reposition 
the nucleosomes and facilitate recruitment of components of the general transcription machinery. 
The activity of AHR is controlled by negative feedback mechanisms, involving ubiquitination and 
proteasome-mediated degradation (McIntosh et al., 2010). Another mechanism is through the 
induction of the aryl hydrocarbon receptor repressor (AHRR) that competes with AHR for 
heterodimer formation with ARNT and prevents the AHR-ARNT binding to the xenobiotic-
responsive elements (XREs) (Oshima, Mimura, Sekine, Okawa, & Fujii-Kuriyama, 2009). The 
clearance of its ligand FICZ is another feedback mechanism. Indeed, FICZ is an AHR ligand and 
activator, but it is also a good substrate for CYP1 enzymes. As a result, the clearance of FICZ by 
the CYP1 results also in the shutdown of AHR pathway (Wincent et al., 2009).  
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Figure 3. Ligand activation of AHR and control by negative feedback mechanisms (Bersten et al., 2013) 
 
1.2.5 AHR functions  
The AHR has been studied for several decades largely in relation to toxicology and pharmacology. 
It was originally identified as a transcription factor responsible for the induction of xenobiotic-
metabolizing cytochrome P4501 (CYP1). Nowadays, research on AHR has expanded into different 
aspects of physiology, such as embryonic and fetal development, glucose and lipid metabolism, 
circadian rhythmicity, and immune, reproductive, cardiovascular and neural systems, (Nebert, 2017; 
Nebert & Karp, 2008). Increasing attention is given today to the role of AHR in tumorigenesis. 
Experimental data has reported the association between AHR and tumor onset, promotion and 
progression (Dietrich & Kaina, 2010; Gasiewicz, Henry, & Collins, 2008; Koliopanos et al., 2002), 
and several works evidenced constitutive AHR activation in different types of tumors (Dever & 
Opanashuk, 2012; Peng et al., 2009), especially in breast cancer (Eltom, Gasmelseed, & Saoudi-
Guentri, 2006; Yang et al., 2005). In particular, a recent study demonstrated high levels of AHR 
expression in TNBC (Triple Negative Breast Cancer) and their metastases (Novikov et al., 2016). 
This cancer is characterized by high proliferation/metastatic grade and capacity to invade 
surrounding tissues, and by the absence of ER, Progesterone Receptor (PR) and Human EGF 
(Epidermal Growth Factor) Receptor 2 (HER2). Interestingly, in TNBC has been found both serum 
and tissue high levels of IL6 (Marotta et al., 2011; Sansone et al., 2007), one of the most involved 
cytokine in inflammation. Roles of AHR, in mutual interplay with IL6, has been explored in several 
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experimental models, and, in particular, Hollingshead group obtained an inflammatory state in 
MCF-7 breast and ECC-1 endocervical cancer cells, through the administration of IL-1B or phorbol 
12-myristate 13-acetate (PMA), in combination with TCDD-induced activation of AHR 
(Hollingshead, Beischlag, Dinatale, Ramadoss, & Perdew, 2008). This treatment resulted in a 
prolonged stimulation of IL6 expression, which was also sustained by REL A, the p65 subunit of 
NF-Kb. 
 
1.3 THE CYTOCHROME P450 (CYP) ENZIMES  
 
The cytochrome P450 represents a family of anciently evolved isoenzymes that exist in bacteria, 
plants and animals, and are responsible for specific endogenous functions including the biosynthesis 
of steroid hormones, prostaglandins, bile acids (Nebert & Russell, 2002). They also constitute the 
major enzyme family capable of catalyzing the oxidative biotransformation of several drugs and 
xenobiotics (Zanger, Turpeinen, Klein, & Schwab, 2008). In humans, the CYP superfamily consists 
of 57 genes and 58 pseudogenes, in comparison to 108 functional and 88 pseudogenes in mice, and 
is divided into 18 families based on protein sequence homology (Nelson et al., 2004). Known also 
as monooxygenases, P450 enzymes include a heme-iron center in which molecular oxygen is bound 
to iron (Mason, 1957), and are located in the smooth endoplasmic reticulum of several tissues. The 
name P450 derives from the spectrophotometric Soret peak of light absorbance at 450 nm showed 
when reduced with NADPH and bound to CO (Omura & Sato, 1962).  
 
1.3.1 CYP1 enzyme family  
The CYP1 enzyme family, a member of the CYP superfamily, is inducible via the ligand-activated 
AHR, and includes three proteins: CYP1A1, CYP1A2, and CYP1B1 (Nelson et al., 2004). The 
CYP1A1 and CYP1A2 genes are located on chromosome 15q24.1 (on chromosome 9 in mice) and 
consist of seven exons and six introns, whereas CYP1B1 consists of three exons located on 
chromosome 2p22.2 (and on chromosome 17 in mouse) (G. I. Murray, Melvin, Greenlee, & Burke, 
2001; Nelson et al., 2004).  
In humans, CYP1A1 induction occurs mostly in extrahepatic tissues such as pancreas, thymus, 
uterus, and small intestine (Ding & Kaminsky, 2003). CYP1A1 metabolizes planar substrates, 
including PAHs, β-naphthoflavone (Nebert, 2017) and tryptophan metabolites. CYP1A2 is 
abundantly expressed in liver (Schweikl et al., 1993) and metabolizes several molecules including 
caffeine and clinically important drugs (Gunes & Dahl, 2008; Zhou, Wang, Yang, & Liu, 2010). 
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CYP1B1, like CYP1A1, is expressed at high levels in extrahepatic tissue: mammary gland, prostate, 
uterus, spleen, thyroid, bone marrow, kidney (Bieche et al., 2007), metabolizes arylamines and 
environmental chemicals including PAHs and biphenyls and has been found overexpressed in 
tumors (G. I. Murray et al., 1997). 
 
1.4 INFLAMMATION 
 
Inflammation is the body’s first response to internal and external harmful stimuli that eliminate the 
aggressor agent and restore the normal tissue physiology. The nature of the stimuli can be physical 
(injuries or radiation), chemical (poisons or toxins) and biological (pathogens like viruses, fungi or 
bacteria).  
The clinical symptoms of inflammation were initially described by a physician in first century 
Rome, Aulus Cornelius Celsus, as calor (heat), dolor (pain), rubor (redness), and tumor (swelling). 
When tissue homeostasis is perturbed, a complex orchestration of events leads to the inflammatory 
process. Several cell types as macrophages and mast cells release mediators of inflammation such 
as cytokines, chemokines and histamine, which induces local vasodilation and increased regional 
blood flow to the inflamed area, microvascular permeability and the mobilization and infiltration of 
leukocytes at the site of injury (de Visser, Eichten, & Coussens, 2006). 
When this process is maintained for a short period of time, it has therapeutic effects that terminate 
with the restoration of the pre-injury state, but if it becomes chronic and uncontrolled it can 
represent a pathophysiologic basis for many diseases such as diabetes, rheumatoid arthritis, 
Alzheimer’s, pulmonary and cardiovascular pathologies, and cancer (Aggarwal, Shishodia, Sandur, 
Pandey, & Sethi, 2006; Medzhitov, 2010). 
 
1.4.1 Inflammation and cancer  
Carcinogenesis is the process in which a normal cell acquires a tumoral phenotype, and is divided in 
three steps: tumor initiation, tumor promotion and tumor progression (Karin & Greten, 2005).  
In the first one, carcinogens induce irreversible changes on DNA, provoking the activation of 
oncogenes and/or the inactivation of suppressor genes. In the second one, risk factors, tumor 
promoters such as viruses, tobacco or chronic inflammation lead mutated cells to expand by 
reducing apoptosis and increasing cell proliferation (Coussens & Werb, 2002; Karin & Greten, 
2005). Finally, invasion of adjacent tissue and development of metastasis characterize the last stage, 
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in which tumor can also accumulate other mutations and acquires tumorigenic proprieties (Karin & 
Greten, 2005).  
In 1863, Rudolf Virchow first postulated the crucial link between chronic inflammation and cancer, 
by noting the presence of leukocytes in tumor biopsies. He proposed that an inflammatory context 
could promote a cellular environment that drives the development of carcinogenesis (Demaria et al., 
2010; Mantovani, 2009).  
Nowadays, it is a well-accepted paradigm that inflammation is linked to cancer, as evidenced from 
a wide range of lines of works in this context (Balkwill, Charles, & Mantovani, 2005; Balkwill & 
Mantovani, 2001; Coussens & Werb, 2002; Hussain, Hofseth, & Harris, 2003; Mantovani, 
Allavena, Sica, & Balkwill, 2008). Epidemiological data indicate that chronic inflammation 
predisposes one to different forms of cancer, and that over 25% of all cancers are related to chronic 
infections (Hussain & Harris, 2007), but the association between inflammation and cancer is not 
only restricted to increased risk for a subset of tumors. Indeed, an inflammatory component is 
represented by the microenvironment of most neoplastic tissues, including those not 
epidemiologically related to inflammatory processes. The microenvironment is supplied by 
bioactive molecules such as growth factor, survival factors, pro-angiogenic factors, and herein 
inflammation contributes to proliferation and survival of malignant cells, aggressiveness of the 
cancer, development of metastasis and angiogenesis, subversion of adaptive immunity and reduced 
response to chemotherapeutic agents. Accordingly, cancer-related inflammation has been included 
as a seventh hallmark of cancer, in addition to the previous six identified by Hanahan and Weinberg 
(Colotta, Allavena, Sica, Garlanda, & Mantovani, 2009; Hanahan & Weinberg, 2011) (figure 4). 
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Figure 4. Inflammation as the seventh hallmark of cancer (Colotta et al., 2009) 
 
In the tumor microenvironment, the inflammation is characterized by the presence of macrophages, 
that secrete angiogenic factors and metalloproteinases (Mantovani et al., 2008) and leucocytes. 
Other involved cells comprise natural killer (NK), dendritic and mast cells, neutrophils, eosinophils 
and lymphocytes. These cells types produce several cytotoxic mediators as reactive oxygen 
intermediates (ROS), membrane perforating agents, serine and cysteine proteases, TNFα, 
interleukins, interferons (INFs), and enzymes such as cyclo-oxygenase-2 (COX-2), 5-lipoxygenase 
(5-LOX). In addition, inflammation increases the expression of NF-κB (nuclear factor κB), STAT3 
(signal transducer and activator of transcription 3), AP-1 (activator protein 1) and HIF-1α (hypoxia-
inducible factor 1α), transcription factors that control the regulation of genes involved in 
proliferation, growth and survival (Aggarwal, 2009; Coussens & Werb, 2002; Mantovani et al., 
2008).  
Among the inflammatory mediators included in the tumor microenvironment, cytokines represent a 
family of molecules which perform different cellular functions, but depending on concentrations 
and tissue specificity can exert both pro- and anti-tumorigenic proprieties (Balkwill & Mantovani, 
2001). The cytokines most involved in inflammation are TNFα, IL4, IL10, IL13, IL1, IL15, IL17, 
IL23 and IL6. 
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1.5 IL6 
 
1.5.1 IL6 pathway  
IL6 is a pleiotropic cytokine that mediates a wide range of physiologic functions in immune 
regulation, hematopoiesis and oncogenesis (Ara & Declerck, 2010; Fielding et al., 2008; Kishimoto, 
2006; Paul, 1991). Depending on cellular context, IL6 is able to signal through different protein 
kinase-dependent proliferation and anti-apoptosis cascades, among which the phosphatidylinositol-
triphosphate kinase (PI-3K)/Akt pathway, the mitogen-activated protein kinase (MAPK) pathway 
and the most implicated in breast cancer Janus kinase (JAK)/signal transducer and activator of 
transcription-3 (STAT3) pathway (Hodge, Hurt, & Farrar, 2005) (figure 5). 
 
Figure 5. IL-6: A pleiotropic cytokine affecting proliferative and anti-apoptotic pathways (Hodge et al., 2005) 
 
The IL6 receptor complex is formed by the ligand-binding protein IL6Rα (also called CD126) and 
the signal transducing component gp130 (or CD130). A family of tyrosine kinases, the Janus 
kinases (JAK), are associated constitutively with gp130 and activated upon IL6 binding (Heinrich et 
al., 2003; Heinrich, Behrmann, Muller-Newen, Schaper, & Graeve, 1998). The activation of JAKs 
leads to tyrosine phosphorylation of STAT3, and translocation of pSTAT3 from the cytoplasm to 
the nucleus, where it recognizes enhancer elements in the promoters of target genes and starts their 
transcription. The termination of the IL6/JAKs/STAT3 pathway is controlled by the SOCS 
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(suppressor of cytokine signaling) feedback inhibitors and PIAS (protein inhibitor of activated 
STAT) proteins (Heinrich et al., 2003).  
 
1.5.2 STAT3  
STAT3 represents the prime transcriptional regulator that mediates IL6 dependent cell growth, 
differentiation and survival signals (Heinrich et al., 1998; Yu & Jove, 2004). STAT3 belongs to the 
STAT family proteins composed by seven currently known members: STAT1, STAT2, STAT3, 
STAT4, STAT5a, STAT5b and STAT6 (figure 6). Structurally STATs present DNA binding 
domains, dimerization domains and activation domains, and are responsible to convey signals from 
cytokines receptors to the nucleus (Yu & Jove, 2004).  
 
 
Figure 6. The STAT family of proteins (Yu & Jove, 2004) 
 
In normal cells, the activity of STATs is tightly regulated by the presence or absence of the 
respective ligand, whereas in tumor cells cytokine receptors can become constitutively activated, for 
example by paracrine expression of their ligands (Heinrich et al., 2003; Hirano, Ishihara, & Hibi, 
2000). Since STATs regulate the expression of genes involved in cell proliferation, apoptosis and 
immune response, permanent activation can have a role in the tumor cell. In fact, constitutively 
activated STATs has been reported in many tumors, and, in particular, STAT3 has the highest 
incidence of constitutive expression when compared with the other members (Hodge et al., 2005) 
(table 2).  
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Table 2. Activated STAT transcription factors in tumor types (Hodge et al., 2005) 
 
Tumour type Activated   STAT factor 
 
Multiple myeloma    STAT3 
Acute lymphocytic leukemia (ALL)  STATI, STAT5 
Chronic lymphocytic leukemia (CLL)  STATI, STAT3 
Acute myelogenous leukemia (AML)  STATI, STAT3, STAT5 
Large granular lymphocyte leukemia 
(LGL)    STAT3 
Chronic myelogenous leukemia   STAT5 
Lung cancer    STAT3 
Breast cancer    STAT3 
Renal cancer    STAT3 
Prostate cancer    STAT3 
Pancreatic carcinoma   STAT3 
Melanoma    STAT3 
Colon carcinoma    STAT3 
Gastric carcinoma    STAT3 
Cervical cancer    STAT3 
Ovarian cancer    STAT3 
Hepatocellular carcinoma   STAT3 
Head and neck cancers   STAT3 
 
 
1.5.3 IL6 functions 
Depending on cellular context and concentration, IL6 can exert both physiologic and pathologic 
roles. Among the physiologic functions, IL6 is involved in normal cell inflammatory processes, 
host immune defence mechanisms, developmental differentiation of lymphocytes, modulation of 
cellular growth, cell proliferation and cell survival and bone formation (figure 7) (Heinrich et al., 
1998; Hodge et al., 2005; Kamimura, Ishihara, & Hirano, 2003; Steelman et al., 2004).  
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Figure 7. IL6 functions (Tanaka & Kishimoto, 2012) 
 
IL6 is controlled by hormonal feedback mechanisms and age-related changes in the hormonal 
balance, such as the decrease in circulating estrogen and androgen, result in elevated IL6 levels. 
Aberrant IL6 expression is associated with different adverse outcomes, such as chronic 
inflammatory disorders, cardiovascular diseases and cancer (figure 8) (Dijsselbloem, Vanden 
Berghe, De Naeyer, & Haegeman, 2004).  
 
 
Figure 8. IL6 gene expression and ageing (Dijsselbloem et al., 2004) 
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Elevated expression of IL6 has been implicated in a wide range of cancers, such as cervical cancer 
(L. H. Wei et al., 2003), colorectal cancer (Belluco et al., 2000), endometrial cancer (Bellone et al., 
2005), lung cancer (Songur et al., 2004), ovarian carcinoma (Zakrzewska & Poznanski, 2001) and 
breast cancer (Garcia-Tunon et al., 2005; Salgado et al., 2003), and is associated with a poor 
prognosis in breast cancer (Bachelot et al., 2003; Salgado et al., 2003; Zhang & Adachi, 1999).  
Furthermore, high levels of IL6 have been demonstrated in the serum of breast cancer patients with 
respect to healthy donors and correlates with advanced breast tumor stages (Kozlowski, 
Zakrzewska, Tokajuk, & Wojtukiewicz, 2003). In the same manner, high serum and tissues levels 
of IL6 has been found in Triple Negative Breast Cancer (TNBC) (Marotta et al., 2011; Sansone et 
al., 2007). In a recent study, it has been studied the role of oncostatin M, a multifunctional cytokine 
that belongs to the IL6 group, in the regulation of AHR in human HepG2 hepatocarcinoma cells, 
and has been demonstrated that oncostatin M modulates AHR expression and activity, thus making 
inflamed cells more prone to bind to xenobiotics and environmental pollutants (Stobbe-Maicherski 
et al., 2013). 
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1.6 MAMMARY GLAND DEVELOPMENT 
 
In mammals, the mammary gland consists of an elaborate network of branched epithelial ducts 
embedded within the mammary fat pat, a complex stroma containing adipocytes, fibroblasts, nerves, 
blood vessels and different immune cells (Polyak & Kalluri, 2010). 
The mammary gland development occurs in three different and regulated stages: embryonic, 
pubertal and reproductive. In the embryonic stage, epithelial/mesenchymal interactions produce the 
rudimentary ductal structure present at birth, which remain quiescent until puberty (Macias & 
Hinck, 2012).   
Prompted by high levels of estrogen and growth hormones such as insulin-like growth factor 1, 
puberty initiates branching morphogenesis, and the end of the rudimentary ducts proliferates and 
swells into different multilayered epithelial structures, known as terminal end buds (TEBs) (Hinck 
& Silberstein, 2005). These structures then undergo processes of elongation, bifurcation and lateral 
branching until reaching the limit of the fat pad, thereby forming a full epithelial tree (Sternlicht, 
Kouros-Mehr, Lu, & Werb, 2006). 
Upon pregnancy, the luminal epithelium proliferates and differentiates into alveoli, which secrete 
milk during lactation. Massive apoptosis initiates the process of involution after lactation, removing 
up to 80% of the epithelium and remodeling back the gland to its pre-pregnancy state (figure 9).  
 
 
Figure 9: Stages of postnatal mammary gland development (Macias & Hinck, 2012) 
 
All the processes involved in driving mammary morphogenesis are orchestrated by molecular 
signals such as growth factors, tyrosine kinases, extracellular matrix molecules and proteases 
(McNally & Martin, 2011), thereby, alterations in signaling implicated in these interactions may 
impair the correct development of the mammary gland. 
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Among its physiologic functions, AHR has shown to be involved in the regulation of the cell cycle, 
cell proliferation and differentiation, and apoptosis (Gonzalez & Fernandez-Salguero, 1998). 
Accordingly, AHR signaling has shown to play a role in the mammary gland development. In fact, 
in Ahr-/- male mice, histology examinations using whole mount techniques have shown that the 
ducts do not fill the whole mammary fat pad, indicating an abnormal ductal development (Huang et 
al., 2016). Similar effects have also been observed in female mice where the AHR was shown to 
impact the mammary gland development. In their work, Hushka and colleges observed that in Ahr-/- 
mice the number of TEBs was reduced by 50% and there was an increase in blunt-ended terminal 
ducts during postnatal development (Hushka, Williams, & Greenlee, 1998). Furthermore, the 
activation of AHR by xenobiotic ligands seems to have a negative effect on milk production, 
resulting in the inability of the mice to nutritionally support their offspring (Vorderstrasse, Fenton, 
Bohn, Cundiff, & Lawrence, 2004). Adipocytes are required for the correct development and 
branching of TEBs. Importantly, AHR is known to crosstalk with peroxisome proliferator activated 
receptors (PPARs) that are involved in the development of adipose tissue and the maintenance of 
lipid and glucose homeostasis, processes important for the mammary gland development and 
function as well (Borland et al., 2014; Shaban et al., 2004).  
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2. AIMS 
 
Historically, there has been a large focus on describing adverse effects of AHR activation by 
environmental pollutants such as dioxins. However, how endogenous AHR signaling is regulated is 
still largely unknown. The aim of this study is to better understand the physiologic interplay 
between AHR and IL6, a cytokine frequently involved in inflammation. It was performed in two 
different experimental approaches: a human breast epithelial cell model (project 1) and a 
Cyp1a1/1a2/1b1(-/-) (CYP1-KO) triple-knockout mouse model (project 2). 
 
Project 1: 
The expression levels of inflammatory cytokine IL6 are strictly regulated by hormonal feedback 
mechanisms and are further progressively increasing with age, due to the menopause/andropause-
associated disturbed hormonal balance. In addition, AHR is constitutively activated in a wide range 
of tumour types, among which the triple negative breast cancers that are characterized by both 
serum and tissue high levels of IL6. Given these findings, in our work we wondered if AHR could 
be regulated by means of IL6-driven inflammation. We started our work from the observation that 
AHR mediates the induction of IL6 in MCF-7 breast and ECC-1 endocervical cancer cells, and that 
oncostatin M, a cytokine that belongs to the interleukin-6 cytokine family, is able to induce AHR 
expression in a STAT3-dependent manner in human HepG2 hepatoma cells. We investigated thus 
whether in breast epithelial cell lines showing a triple negative phenotype, IL6-driven inflammation 
could instigate the expression of AHR, which, in turn, endows endogenous IL6 induction. 
Therefore, in the early stages of inflammation, AHR could assume an active role and sustain 
inflammation.  
 
Project 2: 
CYP1 enzymes play a crucial role in negative feedback mechanisms of AHR activation, and this 
physiologic regulation is of functional importance. CYP1-KO mice are characterized by a 
potentiated activation of AHR due to reduced ligand metabolism. Sustained activation of AHR has 
been linked to damaging effects in several biological processes, resulting in e.g. immunotoxicity, 
endocrine disruption, and development of cancer (Mitchell & Elferink, 2009; Moennikes et al., 
2004). Previous studies have shown that ablation or inhibition of CYP1 enzymes results in AHR-
dependent altered levels of cytokines, moreover AHR activation is able to induce IL6 mRNA levels 
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and is linked with mammary gland cancer (Hollingshead et al., 2008). Recently, a critical function 
of the AHR-dependent CYP1 enzyme family in regulation of AHR functions in gut immunity was 
described (Schiering et al., 2017). The role of CYP1 enzymes in physiological functions of AHR in 
other tissues is however still largely unknown. In the mammary gland, AHR crosstalks with 
multiple signaling pathways that may impact mammary gland development and function. In 
particular, the aim of this study was to determine the impact of altered CYP1/AHR signaling on Il6 
expression and on pathways related to inflammation, cell proliferation and adipogenesis. 
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3. METHODS 
 
Project 1: 
Cell culture and reagents 
The human epithelial breast cancer MDA-MB-231 cell line was maintained in Dulbecco’s Modified 
Eagle’s Medium High Glucose (EuroClone) supplemented with 10% Fetal Bovine Serum (FBS, 
EuroClone), 100 U/mL penicillin, and 100 U/mL streptomycin. The human epithelial non-
tumorigenic MCF10A cells were cultured with Dulbecco’s Mem Nutrient Mix F12 (Euroclone) 
with 25 mM Hepes and L-Glutamine, 10% Fetal Bovine Serum, 100 U/mL penicillin and 100 U/mL 
streptomycin , 20 ng/ml EGF, 10 μg/ml bovine insulin and 0.5 μg/ml hydrocortisone. Both cell lines 
were maintained in a 37°C incubator with 5% CO2. Recombinant Human Interleukin-6 (IL6) was 
purchased from ImmunoTools (Friesoythe, Germany), 6-formylindolo[3,2-b]carbazole (FICZ) from 
Sigma Aldrich and 1,2,6,7,8,9-hexahydro-1,6,6-trimethyl- (R)-phenanthro(1,2-b)furan-10,11-dione 
(Cryptotanshinone) from Selleckchem (Houston, TX , USA).  
 
Real Time  
Total RNA from MCF10A and MDA-MB-231 was extracted with Trizol reagent (Invitrogen Life 
Technologies, Carlsbad, CA) as described by the manufacturer's protocol. RNA purity and quality 
were defined spectrophotometrically by measuring the 260/280-absorbance ratio. The cDNA was 
synthesized from 1 µg of total RNA by use of Improm-II Reverse Transcription System (Promega, 
Madison, WI, USA). Real time polymerase chain reaction (RT-PCR) was performed on a 
Stratagene mx3000p thermocycler (Thermo Fisher Scientific, Waltham, MA USA), using a SYBR 
green supermix (Bio-Rad). The primer sequences were designed using the primer-blast online 
software and were as follows: for β-ACTIN reverse 5’-ATCTGGGTCATCTTCTCGCG-3’, forward 
5’-CAACTGGGACGACATGGAGA-3’, for STAT3 reverse 5’-CTCTTCCAGTCAGCCAGCTC-
3’, forward 5’-CGGAGAAGCATCGTGAGTGA-3’, for IL6 reverse 5’-
AGTGCCTCTTTGCTGCTTTC-3’, forward 5’-AGACAGCCACTCACCTCTTC-3’, for AHR 
reverse 5’-AGTTATCCTGGCCTCCGTTT-3’, forward 5’-CTTCCAAGCGGCATAGAGAC-3’. 
 
Western Blot 
Total proteins were extracted from cells using a cell lysis buffer containing 0,1 M NaCl, 0,01 M 
Tris, 0,001 M EDTA, 0,1% Triton. Equal amounts of proteins were loaded and electrophoresed 
through 10% polyacrylamide gels and were then transferred to nitrocellulose blotting membranes 
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(Amersham, USA). After being blocked for 1 hour using PBS with 0.05% Tween 20 and 5% milk 
powder, membranes were incubated with the following antibodies: rabbit polyclonal Ah Receptor, 
96 kDa (Santa Cruz Biotechnology), rabbit Phospho-STAT3, 79-86 kDa (Cell Signaling 
Technology), mouse STAT3, 79-86 kDa (Cell Signaling Technology), mouse β-Actin, 42kDa 
(Santa Cruz Biotechnology). The following day the membranes were washed with PBS Tween and 
incubated for 1 hour with the appropriate HRP-conjugated secondary antibody. Blots were 
developed using enhanced chemiluminescence (Amersham ECL Detection Reagent), images were 
recorded with Chem Doc XRS+ (Biorad) and analyzed by Image-Lab 3.0 software. 
 
ELISA assay 
5x103 cells were seeded into 96-wells plates, cultured until confluent, and treated with increasing 
doses of IL6 (0, 5, 10, 20, 30 ng/ml) for 24 hours. Cells were abundantly washed with PBS, the 
medium was replaced and the following day the medium of every sample was collected and stored 
at -80°C for subsequent analyses. ELISA assay was performed according to the manufacturer's 
instructions (Biotechnology Komabiotech, Yeongdeungpo-gu, Seoul 07207, Korea). The plate was 
read at 450 nm wavelength by using a microplate reader spectrophotometer (Biorad, Hercules, 
USA) and results were calculated by using a standard curve.  
 
EROD assay 
MCF10A and MDA-MB-231 cells were seeded into 96-well plates at a concentration of 
5x103cells/well, incubated at 37°C and grown until over-confluent. Cells were treated with 
increasing concentrations of IL6 (0, 5, 10, 20, 30 ng/ml). The following day, EROD assay has been 
conducted by using the protocol described by Schiwy (Schiwy et al., 2015). 3 replicates for each 
experimental group were performed. 
 
MTT cell viability assay 
To evaluate the cell viability we performed the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) tetrazolium reduction assay. Cells were seeded into 96-well plates at 
a concentration of 5x103cells/well and incubated overnight. The following day, cells were treated 
with increasing concentrations of IL6 (0, 5, 10, 20, 30 ng/ml) with 3 replicates for each 
experimental group. After 24 hours, the medium was removed from each well, and cells were 
washed with PBS and incubated with 10 µl of MTT reagent for 3 hours at at 37˚C and then with 
100 µl of solubilization solution to dissolve the formazan products. The quantity of formazan was 
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measured by recording changes in absorbance at 570 nm using a microplate reader 
spectrophotometer (Biorad, Hercules, USA) to calculate the proliferation rate. 
 
Flow cytometric analysis 
MCF10A and MDA-MB-231 cells were seeded at a density of 1,3x105 into 6-wells plates, and the 
following day were treated with IL6 0, 5, 10, 20, 30 ng/ml. After 24 hours cells were trypsinized, 
centrifuged, washed with PBS and fixed with 70% cold ethanol. After 20 minutes cells were 
centrifuged twice 5 minutes at 1500 rpm, resuspended in 500 µl of PBS containing 50 µg/ml RNase 
A and incubated at room temperature for 30 minutes. Cells were then centrifuged and resuspended 
in PBS containing 10 µg/ml propidium iodide and cell cycle was analyzed with FACS (BD 
FACSaria cell sorter, BD Bioscences, San Jose, CA, USA). 
 
Wound healing assay  
To analyze the cell migration we performed a wound healing assay. 1,3x105 cells were seeded into a 
6-wells plate, incubated and cultured until confluent. Then, a straight scratch was made on the 
confluent monolayer using a 200 μl pipette tip. The wells were washed to remove the debris and 
cells were treated with IL6 at the concentration of 10 ng/ml in a serum free medium. The growth 
towards the center of the gap was monitored and images were captured at the beginning and at 
regular intervals at two time points during cell migration, after 24 and 48 hours. The average 
percentage of the covered wound area was measured and quantified.  
 
Statistics 
All statistical tests were performed using the GraphPad Prism software Version 6.0. Data are 
presented as mean ±SEM. Statistical comparisons were performed using One sample t test and a 
value of P<0.05 was considered statistically significant. 
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Project 2: 
Mice model   
Mammary gland tissues from C57BL/6 mice were used. We compared the WT phenotype (CYP1-
WT) with the Cyp1a1/1a2/1b1(-/-) triple-knockout (CYP1-KO), generated by crossing the 
Cyp1a1/1a2(-/-) double-knockout mouse with the Cyp1b1(-/-) single-knockout mouse (Dragin et al., 
2008). All mice were bred in the Francis Crick Institute animal facility (London, UK) under 
specified pathogen-free conditions and all tissue analyses were performed at Karolinska Institutet 
(Stockholm, Sweden). All animal procedures were conducted under a Project Licence granted by 
the UK Home Office. For all the experiments, dissected fat pads containing the mammary gland 
tissues from a total of 24 mice were used: 12 females, of which 6 CYP1-KO and 6 CYP1-WT, and 
12 males, of which 6 CYP1-KO and 6 CYP1-WT.  
 
RNA extraction and Real time  
For the gene expression analysis we extracted the total RNA from tree different mammary gland 
tissues from each mouse; one left and one right thoracic and the right abdominal mammary glands. 
Thus in total for each gene we evaluated expression in 18 separate tissues per sex from each genetic 
model. Total RNA was extracted using the AllPrep DNA/RNA/Protein Mini Kit (Qiagen) following 
manufacturer’s instruction and one microgram of total RNA was reverse-transcribed using iScript™ 
Reverse Transcription Supermix for RT-qPCR (BioRad). Quantitative real time PCR was 
performed in a 96-well format 7500 Real Time PCR System (Thermo Fisher Scientific) using 
TaqMan™ Universal Master Mix II and gene-specific TaqManTM probes (Thermo Fisher 
Scientific). Quantification of each gene was calculated using the delta-delta CT method, normalized 
to B2m housekeeping gene and expressed relatively to WT control.  
 
Histology and immunohistochemistry  
For the immunohistochemistry and the histological analysis, the mammary gland tissues were 
formalin-fixed, paraffin-embedded and sectioned at the microtome in slices of 3 µm each. Ki67 
expression (Rabbit, Cell Signaling) was assessed by the immune-peroxidase method, and 
hematoxylin eosin protocol was used for the histology. For each mouse we sectioned one abdominal 
mammary gland, so in total we examined 12 females (6 CYP1-KO and 6 CYP1-WT) and 12 males 
(6 CYP1-KO and 6 CYP1-WT). 
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Statistics  
For the gene expression analysis, differences between groups were analyzed using the two-way 
analysis of variance (ANOVA). Experimental data are expressed as the mean ± SD. P-values less 
than 0.05 were considered statistically significant and less than 0,001 highly significant. Statistical 
analyses were performed using GraphPad Prism version 6.0. 
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4. RESULTS 
 
Project 1: 
 
4.1 IL6 administration stimulates STAT3 and AHR expression through the activation of 
pSTAT3. 
 
Previous experimental data demonstrate that, in human HepG2 hepatocarcinoma cells, the 
pleiotropic interleukin IL6-type cytokine oncostatin M stimulates AHR expression through STAT3 
(Stobbe-Maicherski et al., 2013). Accordingly, with this study, we investigated if IL6 could 
modulate AHR induction in human breast epithelial MCF10A and breast cancer cell line MDA-
MB-231. To do this, we administrated increasing concentrations of IL6, and we evaluated AHR 
gene expression after 24 hours of IL6 treatment. Real time analysis showed a slight enhancement in 
MDA-MB-231 cells, and a significant increase of AHR expression in MCF10A cells (fig. 1A, 1B). 
We then analyzed STAT3 mRNA expression and we observed a similar increasing trend in both cell 
lines (fig. 1C, 1D). Thereafter, in order to investigate the phosphorylated form of STAT3 and 
whether the increase in AHR and STAT3 expression was confirmed also at the protein level, we 
evaluated these markers by western blot. Similarly, after 24 hours of IL6 treatment, we observed an 
enhanced expression of AHR, STAT3 and pSTAT3 proteins in both cell lines (fig. 1E, 1F). These 
data suggest a link between STAT3 activation and AHR induction. Consequently, in order to further 
investigate their association, we inhibited STAT3 phosphorylation and evaluated the AHR 
expression. We used Cryptotanshinone (CPT) as inhibitor, a natural quinoid diterpene isolated from 
the roots of the plant Salvia miltiorrhiza Bunge. Specifically, this molecule strongly inhibits the 
STAT3 phosphorylation at the Tyr705, and prevents the dimerization of STAT3. As expected, 
following administration of increasing concentrations of CPT, we observed a dose-dependent 
decrease of pSTAT3 expression, and, interestingly, an AHR decreased expression simultaneously 
occurred, supporting the dependence of AHR expression from STAT3 activation (fig. 1G, 1H). 
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Figure 1 (A, B, C, D). Effects of IL6 on gene expression. Cells were treated with 0, 5, 10, 20, 30 ng/ml of IL6. After 
24 hours transcriptional levels of AHR and STAT3 were analyzed. Relative mRNA expression was measured by qRT-
PCR using 2(-ΔΔCt) method (n=3). The results are expressed as mean±SEM; *p<0.05 
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Figure 1. (E, F) Effects of IL6 on protein expression by western blot analysis. Bar graphs and representative gel 
blots of AHR, pSTAT3, STAT3 proteins. Cells were treated with 0, 5, 10, 20, 30, 50 ng/ml of IL6. After 24 hours, 
protein expression was analyzed. Each band was quantified using densitometry and normalized to the respective β-
Actin (n=3). The results are expressed as mean±SEM. (G, H) Inhibitory effects of Cryptotanshinone (CPT) on AHR 
and pSTAT3 expression. Bar graphs and representative gel blots of AHR, pSTAT3 and STAT3 proteins. Cells were 
treated with 0, 4, 6, 8, µM of CPT. After 24 hours protein levels were analyzed. Each band was quantified using 
densitometry and normalized to the respective β-Actin (n=3). The results are expressed as mean±SEM.  
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4.2 The induction of endogenous IL6 is regulated by IL6 administration and by AHR 
activation. 
 
To determine if the administration of exogenous IL6 could generate an auto-inflammatory loop, we 
evaluated whether IL6 could, on the other hand, enhance the production of endogenous IL6. In 
Hollingshead’s work, activation of IL6 gene and the secretion of the cytokine as a consequence of 
AHR stimulation has been shown (Hollingshead et al., 2008).  
Initially, we evaluated IL6 mRNA after 24 hours of exogenous IL6 administration. We observed in 
both cell lines a dose dependent increasing trend in IL6 expression (fig. 2A, 2B). Then, through 
ELISA test, we investigated the endogenous IL6 secretion after 24 hours from the removal of 
increasing doses of exogenous IL6 (fig. 2C, 2D). Similarly, in both cell lines, endogenous IL6 
secretion was still present and it was proportional to the exogenous inflammatory stimulus. We 
could expect this result as the establishment of a sustained secretion of IL6 could be a consequence 
of the increased gene expression of IL6, and required some time to be released in the medium.  
In order to evaluate the expression levels of AHR and inflammatory parameters in post-
inflammatory state following the suspension of the IL6 administration, we analyzed their gene 
expression after removing the IL6 stimulus. Interestingly, two different patterns were observed in 
the two cell lines, in particular, in MCF10A, IL6 and STAT3 slightly decreased in their expression 
(fig. 2E), suggesting a gradual shutdown of the endogenous inflammation. In MDA-MB-231, these 
inflammatory parameters slightly enhanced their expression (fig. 2F). Interestingly, in both cell 
lines we observed a significant reduction of AHR.   
In order to evaluate the possible contribution of AHR in the expression of IL6, we decided to treat 
cells with 6-formylindolo [3,2-b] carbazole (FICZ), a tryptophan metabolite and a high affinity 
AHR ligand, and to analyze the IL6 mRNA expression once that AHR was activated. We observed 
that in MCF10A, the activation of the receptor (FICZ+/IL6-) caused a significant increased IL6 
gene expression (fig. 2G), and that the activation of the receptor, in conjunction with IL6 
administration (FICZ+/IL6+) induced a more pronounced expression of IL6, suggesting that both 
AHR activation both IL6-induced inflammation cooperate to the increase endogenous IL6 
expression.  
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Figure 2. (A, B) Effects of IL6 on gene expression. Cells were treated with 0, 5, 10, 20, 30 ng/ml of IL6. After 24 
hours, transcriptional levels of IL6 were analyzed. Relative mRNA expression was measured by qRT-PCR using 2(-
ΔΔCt) method (n=3). The results are expressed as mean±SEM; *p<0.05. (C, D) Evaluation of IL6 secretion. After 
treating the cells with increasing doses of IL6 (0, 5, 10, 20, 30 ng/ml) for 24 hours, cells were washed with PBS and 
incubated with new culture medium. The following day, IL6 secretion was analyzed by ELISA assay (n=3). The results 
are expressed as mean±SEM.  
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Figure 2. (E, F) Transcriptional levels after IL6 treatment, by qRT-PCR. Cells were treated with IL6 10 ng/ml. The 
following day, IL6 was removed, the cells were washed in PBS and incubated with new culture medium without IL6 for 
24 hours. Relative mRNA expression of IL6, STAT3 and AHR was measured by qRT-PCR using 2(-ΔΔCt) method 
(n=3). The results are expressed as mean±SEM; *p<0.05. (G, H) Effects of FICZ and IL6 on gene expression. Cells 
were treated with IL6 10 ng/ml and/or FICZ 50 nM for 24 hours and IL6 gene expression was quantified. Relative 
mRNA expression was measured by qRT-PCR using 2(-ΔΔCt) method (n=3). The results are expressed as mean±SEM; 
*p<0.05. 
  
4. Results 
 
 
 
  37 
 
4.3 IL6 affects cell cycle progression and migration activity. 
 
To evaluate the role of AHR under inflammatory conditions, we treated cells with increasing 
concentrations of IL6 and subsequently we performed the 7-ethoxy-resorufin-O-deethylase (EROD) 
assay. This test is employed in the evaluation of the induction of an AHR-induced xenobiotic-
metabolizing enzyme, the AHR target gene cytochrome P-450 (CYP)1A1. In both cell lines, the 
treatment with IL6 which, as anticipated, endowed the increase of AHR gene expression, did not 
cause significant changes in the CYP1A1 activity (fig. 3A, 3B). We could therefore exclude any 
role in toxicological signaling and hypothesize its possible role in proliferation, cell cycle 
progression and migration.  
We then performed the MTT, a colorimetric assay utilized to measure the cell viability. In this test, 
the MTT tetrazole is reduced to purple formazan in living cells and the absorbance of each well 
quantified by a spectrophotometer provides the respective cell metabolic activity. We did not 
observe significant variations in the cell viability at any IL6 concentrations (fig. 3C, 3D) and as this 
result could be interpreted as a clue of cell cycle block, we decided to analyze the cell cycle 
progression through flow cytometry. Both cell lines were treated with usual increasing 
concentrations of IL6, and cell cycle was assessed with propidium iodide. In MCF10A, we did not 
find an effect at the 5 ng/ml concentration (data not shown) and instead, we observed a significant 
arrest in the cell cycle progression at the concentrations of 10, 20 and 30 ng/ml of IL6 (fig. 3E). In 
fact, non treated (NT) cells exhibit a G1 value of 49,2, and the treated ones a value of 61 (at 10 
ng/ml), of 61,4 (at 20 ng/ml) and of 57 (at 30 ng/ml). Conversely, in MDA-MB-231 we could not 
evidence any alteration in the cell cycle progression after administration of IL6, as illustrated in the 
plot in fig. 3E in which the overlapping of the cell phases picks of the not treated and treated cells is 
shown.  
We then evaluated the cell migration with a scratch test. We chose the 10 ng/ml dose of IL6 to treat 
cells since it is the concentration starting from which we could observe an effect in the cell cycle 
progression. Interestingly, we found an increase in the migration activity in both cell lines, 
statistically significant in the MCF10A (fig. 3F, 3G). 
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Figure 3. (A, B) Effects of IL6 on enzymatic activity by EROD assay. Cells were treated with 0, 5, 10, 20, 30 ng/ml 
of IL6 and the following day the induction of the xenobiotic-metabolizing enzyme cytochrome P-450(CYP)1A1 was 
quantified through spectrometry (n=3). The results are expressed as mean±SEM. (C, D) Effects of IL6 on cell viability 
by MTT assay. Cells were seeded and treated with 0, 5, 10, 20, 30 ng/ml of IL6 for 24 hours. Cells were treated with 
MTT reagent and solubilization solution and the absorbance levels were measured through spectrophotometry (n=3). 
The results are expressed as mean±SEM. 
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Figure 3. (E) MCF10A and MDA-MB-231 cell cycle analysis with PI. After treating cells with 0, 5, 10, 20, 30 ng/ml 
of IL6, cell cycle distribution was analyzed through FACS flow cytometer. Plots show the G1, S and G2M phases. 
Compared with non-treated control (NT), MCF10A cells treated with 10, 20, 30 ng/ml of IL6 were arrested in G1 
phase. No differences in cell cycle distribution in treated and control MDA-MB-231 were seen, as shown in the 
overlapping of the cell phases picks of the control and treated cells. (F, G) Effects of IL6 on migration using a wound 
healing assay. Cells were scratched with a 200 pipette tip and the migration was observed at 0 hours (T0), 24 hours 
(T1) and 48 hours (T2), in cells treated with 10ng/ml of IL6 (IL6) and in control non-treated cells (NT). Average 
percentage of the covered wound area was quantified (n=3). The results are expressed as mean±SEM; *, p<0.05.  
4. Results 
 
 
 
  40 
 
Project 2: 
 
4.4 AHR/CYP1 disrupted signaling affects Pparγ and Ahr transcription and mammary gland 
tissue morphology 
 
To explore the meaning of the loss of the CYP1 enzymatic activity and the subsequent effects on 
inflammatory and adipogenesis-related markers and on cell proliferation pathways, we employed 
three different approaches. First, gene expression analyses of Ahr, Il6 and Pparγ through 
quantitative real time PCR were performed. Then, histological analyses of the mammary gland 
tissues from CYP1-KO and CYP1-WT mice were conducted. Both male and female mice were 
included to determine sex-dependent effects in addition to the genotype-dependent effects. Last, we 
investigated the expression of the proliferation marker Ki67, through immunohistochemistry in 
order to evaluate whether there were effects on cell proliferation and in the development of the 
mammary gland. 
From the gene expression results, in female mice we could observe a highly significant 
downregulation of Pparγ in the CYP1-KO genotype, compared to the WT (fig. 4A), while no 
effects on Il6 expression were observed. A tendency toward increased Ahr expression was observed 
in female CYP1-KO mice, although not in a statistically significant way (p-value = 0,0597). 
Furthermore, this indication is strengthened by the fact that the analysis of Ahr expression in each 
separate mammary gland tissue shows a significant enhancement of Ahr mRNA in one of three 
thoracic mammary glands (fig. 4B). In male mice, we did not find a significant difference in Ahr or 
Il6 expression, and, above all, no effects in the expression of Pparγ was observed, neither in the 
separate mammary gland tissues (not shown) or pooled data (fig. 4C).  
We did not find any difference in the proliferation marker Ki67 between the females, males, CYP1-
KO and CYP1-WT (fig. 4D), while, from the histological analysis, we could evidence some 
alterations in the morphology of the tissue. In female mice, we found a clear difference in the 
number of ductal structures embedded in the whole fat pad, where the CYP1-KO presented a lower 
number of ducts compared with the CYP1-WT control (fig. 4E). This characteristic was exhibited in 
three of the six CYP1-KO female mice, i.e. in 50% of the total number of the samples. Another 
interesting feature that we observed was the difference in the composition of the liquid inside the 
ductal structures. In the female CYP1-KO mice the secretions were more abundant and apparently 
fattier, with a lipid composition (fig. 4F).  
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4C 
 
 
Figure 4 (A, B, C). Effects of altered CYP1/AHR signaling on gene expression. (A) Ahr, Il6, Pparγ gene expression 
in mammary gland tissues from female mice, CYP1-WT and CYP1-KO (n=18 mammary glands from 6 mice). Error 
bars represent mean ± S.D. ***P < 0.001, calculated by two-way ANOVA. (B) Ahr gene expression in one of the 
thoracic mammary glands (n=6 mammary glands from 6 mice), from female CYP1-WT and CYP1-KO. Error bars 
represent mean ± S.D. *P < 0.05 calculated by two-way ANOVA. (C) Ahr, Il6, Pparγ gene expression of mammary 
gland tissues in male mice, CYP1-WT and CYP1-KO (n=18 mammary glands from 6 mice). Error bars represent mean 
± S.D.                   
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Figure 4 (D). Effects of altered CYP1/AHR signaling on proliferation. Ki67 expression in female CYP1-WT and 
CYP1-KO assessed by the immune-peroxidase method. Scale bar 200 µm.  
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Figure 4 (E). Effects of altered CYP1/AHR signaling on morphology and proliferation. Histological analysis of 
representative female CYP1-WT and CYP1-KO mammary gland tissues showing reduced number of ductal structures 
in female CYP1-KO compared to CYP1-WT. Hematoxylin eosin staining, scale bar 5000 µm.  
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Female CYP1-WT 
 
 
Female CYP1-KO 
 
 
Figure 4 (F). Effects of altered CYP1/AHR signaling on morphology. Histological analysis of representative female 
CYP1-WT and CYP1-KO mammary gland tissues showing the apparent diverse composition of the secretion inside the 
ducts. Hematoxylin eosin staining, scale bar 500 µm.  
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5. DISCUSSION 
 
In project 1, we provided some pieces of evidence suggesting the participation of AHR to IL6-
driven acute inflammation in human breast cells. The focus of the research was to investigate a 
possible connection between the environmental biosensor AHR and inflammation, which today is 
demonstrated to be one of the most influencing risk factors in the development of cancers. This 
issue is of pivotal importance, as the consequences of a mutual interplay between AHR and IL6 
could represent one of the first steps in leading to chronic inflammation. Shedding light on this 
topic is even more urgent in those types of cancers that do not currently have therapies. In this 
respect, we decided to use in our study the MCF10A cell line, a non-tumoral human breast cell line 
that does not express HER2, ER and PR. These markers, which support the growth of steroid 
positive breast cancers, are absent in the TNBC phenotype. Due to the absence of these 
pharmacological targets, TNBC cannot be treated with hormonal therapy (aromatase inhibitors or 
tamoxifen) or with trastuzumab, which is an antagonist of HER2 receptor. Aging is characterized by 
a menopause/andropausa-associated alteration of the physiologic hormone balance and, in 
particular, a decrease of estrogen and androgen was observed. Interestingly, this rapid decline 
correlates with the progressive increase of the inflammatory cytokine IL6, both in serum and breast 
tissues (Papanicolaou, Wilder, Manolagas, & Chrousos, 1998), thus increasing the inflammatory 
state that is considered a risk factor for cancer. Not surprisingly, the incidence of BC rises in the 
second middle of life, in the pre- or post-menopausal period, when sexual steroid hormones 
gradually decrease. In this context, the participation of AHR to the IL6-driven inflammatory 
pathway, which instigates BC, has been frequently described (Goode, Pratap, & Eltom, 2014; Jin, 
Lee, Pfent, & Safe, 2014). Because of this, AHR has often been proposed as a candidate marker 
which can play a role in the development of TNBC. Furthermore, it is recognized that AHR might 
influence tumor development, and an increased activation of AHR is likely to enhance basal AHR 
activity in carcinogenesis, especially given the systemic exposure to AHR agonist ligands derived 
from emission pathways such as wood burning, hospital waste incineration but also from the food 
chain and microbial sources.  
The tight link between inflammation and AHR expression has been efficaciously showed by 
Hollingshead group (Hollingshead et al., 2008). They in fact evidenced an enhancement of IL6 
expression in MCF-7 breast and ECC-1 endocervical cancer cells when inflammation was 
combined with AHR stimulation. More recently, Stobbe-Maicherski and colleagues (Stobbe-
Maicherski et al., 2013) showed the STAT3 dependent stimulation of AHR in HepG2 cells treated 
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with Oncostatin M, a cytokine belonging to the interleukin-6 family. Starting from these data, we 
tried to understand if in a human epithelial breast cell model showing a triple negative phenotype, 
IL6-driven inflammation could instigate the expression of AHR, which, in turn, endows 
endogenous IL6 expression. Ultimately, we hypothesized an auto-inflammatory loop driven by IL6 
administration at the beginning and sustained by AHR afterwards. This issue is of pivotal 
importance, as modulation of inflammation could explain the diverse individual susceptibly to some 
environmental ligands of AHR, which have an impact on human health.  
To test our hypothesis, we initially generated an IL6-driven acute inflammatory experimental design 
in both MCF10A and MDA-MB-231, by treating cells for 24 hours with increasing doses of IL6. 
We confirmed Stobbe-Maicherski’s results, as the expression of AHR mRNA and protein showed 
an IL6 dose-dependent increase. STAT3 mRNA and protein expression increased consistently, as 
did the phosphorylated form pSTAT3. These results highlight the activation of the pathway 
IL6/STAT3 in both cell lines and, intriguingly, draw attention to the concomitant activation of AHR. 
Given the correlation between AHR and pSTAT3 expression, we decided to evaluate AHR protein 
after inhibiting the STAT3 pathway, using Cryptotanshinone, a specific inhibitor of the 
phosphorylation of STAT3. Intriguingly, we could find a dose dependent correlation in the decrease 
of pSTAT3 and of AHR, confirming a tight link between the two pathways. 
Thereafter, starting from Hollingshead’s data, we tested the possible establishment of an auto-
inflammatory loop which produces supplementary, endogenous IL6. We firstly analyzed the 
expression of IL6 mRNA in inflamed cells, where we showed that it increased in both cell lines. 
Consistently, IL6 secretion was enhanced. This result is particularly interesting, especially when 
considering that tumoral MDA-MB-231 cell line displays an inflammatory phenotype which is 
endowed by endogenous IL6 expression (Faggioli et al., 1996). Conversely, in our experimental 
model, MCF10A is a non-transformed cell line which, following an acute inflammatory stimulation, 
turns to an inflammatory phenotype which stimulates AHR expression. 
In post-inflammatory state, we observed two different behaviors of the cell lines. In MCF10A, we 
observed the concomitant reduction of AHR, IL6 and STAT3, while in MDA-MB-231 AHR 
decreased, and IL6 and STAT3 slightly increased. These results suggest that AHR could be a critical 
mediator in inflammatory conditions in non tumorigenic cells, as it can exacerbate IL6 production 
only when inflammation occurs. In post-inflammatory state, when the exogenous administration of 
IL6 is lacking, its expression decreases, together with a reduction of endogenous IL6 and STAT3 
endogenous expression. This suggests the need of a chronic inflammation stimulus to maintain the 
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loop, and AHR could be considered as a sort of inflammatory amplifier and not an inducing factor. 
In contrast, in MDA-MB-231, the decrease of AHR expression coupled to IL6 and STAT3 increase, 
indicate that in these cells AHR is only a participant in a complex framework where the leading 
actor is IL6-induced inflammation. 
In understanding to what extent AHR could sustain IL6 endogenous expression, we focused on the 
cytokine induction after AHR activation. We treated cells with FICZ, a powerful AHR agonist, and 
once AHR was activated, we confirmed an increased IL6 expression in both cell lines, although in 
MDA-MB-231 the increase was not significant. This effect is even more remarkable in combination 
with IL6 treatment, suggesting a reinforcement between the two molecules in exerting the effect.  
We were then interested in evaluating if IL6 could modulate the oxidative stress, since AHR is a 
mediator of the cellular toxicological effects, however we did not find a correlation between IL6-
driven inflammation and EROD activity. We could thus exclude any role in toxicological signaling. 
Certainly, AHR and IL6 regulate physiologic functions such a viability, cell cycle and migration. In 
our experimental conditions, we did not observed differences in cell viability, in both cell lines, 
while the results on the IL6 effects on migration and cell cycle progression were unexpected, in fact 
in MCF10A the enhanced migration caused by IL6 was associated with an arrest in G1 phase of the 
cell cycle. This is an interesting finding since the deregulation of the cell cycle is one of the key 
events in the development of a malignancy, and IL6 can induce a change in the phenotype of the 
non-tumoral MCF10A cells from a proliferative state to an invasive one, indicating that 
proliferation is not always associated with invasion. This step is not required in MDA-MB-231 cell 
line, as its phenotype is tumoral and invasive and, for this reason, does not need a slowing of cell 
cycle to acquire migratory abilities. In a recent study, a FICZ-induced cell cycle arrest in LoVo cells 
has been demonstrated (Yin et al., 2016) and we then suggest that the increase of AHR expression 
induced by IL6 administration tended to arrest MCF10A cell cycle in G1 phase. Nonetheless, 
further studies are needed to confirm it. In conclusion, this study sheds light on the mutual interplay 
between IL6/STAT3 pathway and AHR and on the role of this transcription factor in IL6-driven 
inflammation in breast cells. Altogether, we demonstrated that in the complex puzzle of early steps 
of inflammation, in MCF10A cell line AHR could assume an active role and sustain inflammation. 
This ability, along with its role as a sensor for xenobiotics, could explain the high incidence of 
inflammatory diseases associated to AHR ligands exposition in humans.  
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Project 2: 
AHR represents a ligand dependent transcription factor activated by xenobiotics and natural 
compounds such as tryptophan metabolites, and it is involved in several physiological functions. 
Hence, dysregulation of the AHR pathway can affect different biological processes. The regulation 
of AHR is controlled by feedback mechanisms with the AHR-regulated cytochrome P4501 (CYP1) 
enzymes, which was recently shown to be critical for immune homeostasis in the gut (Schiering et 
al., 2017). Several studies have described a role for AHR signaling in the mammary gland 
development, and, in the present work, we showed that impaired CYP1/AHR-feedback signaling 
affects Pparγ and Ahr transcription and mammary gland ducts morphology.  
We found no changes in Il6 expression in female or male CYP1-KO mice, and from the histological 
analysis no inflammatory phenomena were observed, such as infiltration of macrophages or other 
types of inflammatory cells, suggesting that although the CYP1-KO mouse model presents 
increased levels of AHR activation, altered CYP1/AHR signaling does not interfere with IL6-
related inflammatory pathways. 
In the female CYP1-KO mice, we observed a highly significant downregulation of Pparγ, and a 
reduced number of epithelial ductal structures. These effects could be linked, since Pparγ is a 
central regulator of the adipocytes development, and adipocytes are required for the correct 
development and maintenance of the mammary ductal architecture. The mammary gland epithelial 
tissue is embedded in the fat pad, a heterogeneous stroma containing different amount of both white 
and brown adipose tissue, and it has been shown that selective ablation of mammary adipocytes 
results in the block of the formation and branching of TEBs (Landskroner-Eiger, Park, Israel, 
Pollard, & Scherer, 2010). Moreover, mice lacking white adipose tissue show mammary ducts 
unable to grow and branch normally (Couldrey et al., 2002). Thus, we could hypothesize that the 
downregulation of Pparγ could be involved in the altered ductal structures. However, from the 
immunohistochemical analysis, no defects in proliferation were observed, and, a reduced number of 
ductal structures was only observed in the half of the total number of samples. To further 
investigate this connection, we are analyzing RNA sequencing data in order to evaluate alterations 
in expression of Pparγ upstream or downstream genes and to get a more comprehensive view on 
pathways affected. In addition, more analysis should be performed, such as bromodeoxyuridine 
(BrdU) assay to evaluate proliferation, or TUNEL test to study apoptosis, or whole mounts to better 
recognize the ductal structures; more investigation aimed at understanding the mechanisms that lead 
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to the downregulation of Pparγ in the female CYP1-KO is required. Given the lipid appearance of 
the liquid inside the ducts in the female CYP1-KO, we could hypothesize that the altered Pparγ 
expression may be involved also in the difference of the secretions, but more detailed studies would 
be necessary to investigate it.  
In male mice, no downregulation of Pparγ was observed, suggesting a different mechanism and role 
of CYP1 in regulation of this adipogenesis-related marker compared to female mice. 
In the female CYP1-KO mice, a significant upregulation of Ahr in one of the thoracic mammary 
glands was also observed. Pooling all the Ahr expression data from the three different mammary 
gland tissues from each mouse, the significance is lost, but the p-value still remains close to the 
significance level. To date, it is not very well known how the expression of AHR itself is regulated, 
and there are contradictory studies regarding this topic. However, among the investigated 
mechanisms, it is known that AHR activation induces the transcription of Ahr, which could explain 
the upregulation observed in our study.   
Taken together, these results show the effects of disrupted CYP1/AHR-feedback signaling on 
mammary gland. Every day, we are exposed to chemicals which may act as CYP1 inhibitors, as 
well as AHR activators, mostly derived from endogenous sources, but also from industrial emission 
pathways, the diet and microbial sources. Thus, an altered CYP1/AHR pathway could represent a 
novel toxic mode of action leading to impaired physiological processes.  
Finally, the CYP1-KO mouse model provides a very good in vivo model to investigate the 
physiological roles of CYP1 enzymes. However, additional experiments need to be performed to 
better understand the molecular mechanisms underlying the CYP1-mediated effects. Firstly, the 
same parameters evaluated in this study could be repeated in mice with permanent knockout of Ahr 
(Ahr(-/-), AHR-KO). This mouse model has no functional AHR and, consequently, all downstream 
genes regulated by AHR are affected, including the CYP1 enzymes. The comparison among the 
CYP1-KO and the AHR-KO mice models should allow the differentiation between AHR-dependent 
functions and AHR-regulated CYP1-dependent functions. To further discriminate between AHR- 
and CYP1-dependent functions, a third comparison using a recently developed Cyp1a1-
overexpressing mouse model could be performed (Schiering et al., 2017). Moreover, to better 
evaluate morphodynamic effects and changes on the organization of the ductal structures and the 
branching of the terminal end buds, whole mounts of the mammary fat pads should be performed. 
In parallel, since AHR has recognized roles in the immune and endocrine systems, it is of interest to 
5. Discussion 
 
 
 
  52 
 
extend the analysis performed in this study to other tissues, such as pituitary-, adrenal-, and thyroid 
glands, pancreas, liver, white- and brown adipose, ovary and testis. 
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